Lexeo Therapeutics, Inc.
LXEOLexeo Therapeutics is a clinical-stage genetic medicine company focused on developing AAV-based gene therapies for cardiovascular and neurodegenerative diseases.
Table of contents
Earnings
Next report
Aug 13, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Lexeo Therapeutics is a clinical-stage genetic medicine company focused on developing AAV-based gene therapies for cardiovascular and neurodegenerative diseases. The company leverages a proprietary Sf9 baculovirus manufacturing platform to produce high-quality viral vectors at scale for both rare and prevalent patient populations. Its core value proposition lies in targeting the underlying genetic causes of devastating conditions with high unmet medical need, particularly those affecting heart health.
A clinical-stage pioneer in AAVrh10-based cardiac gene therapy with a proprietary scalable manufacturing process.
Questions, answered.
- What is Lexeo Therapeutics, Inc.'s market cap?
- Lexeo Therapeutics, Inc. (LXEO) has a market capitalization of $351.0M and trades on NASDAQ.
- Who are Lexeo Therapeutics, Inc.'s competitors?
- Lexeo Therapeutics, Inc.'s key competitors include Tenaya Therapeutics Inc., Rocket Pharmaceuticals Inc., Larimar Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Lexeo Therapeutics, Inc. partner with?
- Lexeo Therapeutics, Inc.'s notable partners include Cornell University, The Regents of the University of California, Adverum Biotechnologies, Inc., and others.
- What subsidiaries does Lexeo Therapeutics, Inc. have?
- Lexeo Therapeutics, Inc.'s subsidiaries include Stelios Therapeutics, Inc..
- Where is Lexeo Therapeutics, Inc. headquartered?
- Lexeo Therapeutics, Inc. is headquartered in United States of America and employs approximately 61 people. It has been publicly traded since 2023.